SUBSCRIBE
SUBSCRIBE

Fortis Therapeutics

NEWS
What You Need to Know About Fortis Therapeutics
Business
What You Need to Know About Fortis Therapeutics
Fortis Therapeutics is focused on immuno-oncology, specifically on developing an ADC for multiple myeloma and late-stage prostate cancer, including both the adenocarcinoma and neuroendocrine types.
December 6, 2017
 · 
3 min read
 · 
Mark Terry
NextGen Bio Class of 2018
Bio NC
Top 20 Life Science Startups to Watch in 2018
BioSpace is proud to present its NextGen “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
December 4, 2017
 · 
9 min read
 · 
Mark Terry
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Cancer Immunotherapy Startup Fortis Therapeutics Launches With $18 Million Series A
September 27, 2016
 · 
2 min read
IN THE PRESS
Biotech Beach
Fortis Therapeutics Closes $40 Million Series A Financing to Advance Novel Anti-CD46 Therapeutic to Treat Late-Stage Prostate Cancer and Multiple Myeloma
March 29, 2021
 · 
3 min read
FDA
Fortis Therapeutics Receives FDA Clearance of Two IND Applications for Novel Anti-CD46 Therapeutic for Treatment of Late-Stage Prostate Cancer and Multiple Myeloma
November 6, 2018
 · 
3 min read
Business
RubrYc Therapeutics appoints Jean Viret, Ph.D. to its Board of Directors
November 6, 2018
 · 
1 min read
AWARDS
  • NextGen Class of 2018
JOBS